Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967284043> ?p ?o ?g. }
- W2967284043 endingPage "422" @default.
- W2967284043 startingPage "410" @default.
- W2967284043 abstract "Staphylococcus aureus (S. aureus), including methicillin-resistant S. aureus (MRSA), is an important aetiological cause of community-acquired pneumonia (CAP) and associated with significant morbidity and mortality. Empiric therapy for CAP frequently consists of β-lactam monotherapy or β-lactam/macrolide combination therapy. However, such agents are often ineffective against S. aureus and do not reflect the emergence and increasing prevalence of MRSA in the community setting. Ceftaroline fosamil is a fifth-generation parenteral cephalosporin with broad-spectrum activity against Gram-positive pathogens - such as S. aureus (including MRSA), Streptococcus pneumoniae and Streptococcus pyogenes - and typical Gram-negative pathogens, including Haemophilus influenzae and Moraxella catarrhalis. The approval of ceftaroline fosamil in the United States and Europe for the treatment of adults with moderate-to-severe CAP was based on two phase 3 trials (FOCUS 1 and 2), which demonstrated that ceftaroline fosamil was non-inferior to ceftriaxone, a standard empiric treatment for CAP, while exhibiting a comparable safety profile. Although head-to-head trials of ceftaroline fosamil versus comparators against MRSA CAP are lacking, the effectiveness of ceftaroline fosamil in subpopulations of patients not covered by phase 3 trials (e.g. those with MRSA CAP or severe renal impairment) has been demonstrated in the Clinical Assessment Program and Teflaro Utilization Registry (CAPTURE) study. As ineffective empiric therapy is associated with adverse outcomes, including mortality and increased costs, ceftaroline fosamil, with its extended spectrum of activity, is an attractive alternative to standard antibiotic CAP regimens." @default.
- W2967284043 created "2019-08-22" @default.
- W2967284043 creator A5000138150 @default.
- W2967284043 creator A5014348590 @default.
- W2967284043 creator A5020992600 @default.
- W2967284043 creator A5084519339 @default.
- W2967284043 date "2019-10-01" @default.
- W2967284043 modified "2023-10-12" @default.
- W2967284043 title "Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults" @default.
- W2967284043 cites W1510167967 @default.
- W2967284043 cites W1787158122 @default.
- W2967284043 cites W1890351102 @default.
- W2967284043 cites W1907075739 @default.
- W2967284043 cites W1912035542 @default.
- W2967284043 cites W1963980193 @default.
- W2967284043 cites W1972580838 @default.
- W2967284043 cites W1974614432 @default.
- W2967284043 cites W1978077150 @default.
- W2967284043 cites W1988270723 @default.
- W2967284043 cites W1989385260 @default.
- W2967284043 cites W1993697234 @default.
- W2967284043 cites W1993746671 @default.
- W2967284043 cites W1998378687 @default.
- W2967284043 cites W2000714505 @default.
- W2967284043 cites W2002238893 @default.
- W2967284043 cites W2004431245 @default.
- W2967284043 cites W2007174729 @default.
- W2967284043 cites W2012505215 @default.
- W2967284043 cites W2012617927 @default.
- W2967284043 cites W2016257152 @default.
- W2967284043 cites W2020918341 @default.
- W2967284043 cites W2021359832 @default.
- W2967284043 cites W2022149272 @default.
- W2967284043 cites W2023181056 @default.
- W2967284043 cites W2030302405 @default.
- W2967284043 cites W2032422158 @default.
- W2967284043 cites W2032447526 @default.
- W2967284043 cites W2033143941 @default.
- W2967284043 cites W2036989796 @default.
- W2967284043 cites W2040052393 @default.
- W2967284043 cites W2051279180 @default.
- W2967284043 cites W2051367912 @default.
- W2967284043 cites W2052940624 @default.
- W2967284043 cites W2057909358 @default.
- W2967284043 cites W2063501629 @default.
- W2967284043 cites W2063994252 @default.
- W2967284043 cites W2066482511 @default.
- W2967284043 cites W2071260810 @default.
- W2967284043 cites W2080750440 @default.
- W2967284043 cites W2086334470 @default.
- W2967284043 cites W2088319417 @default.
- W2967284043 cites W2089148193 @default.
- W2967284043 cites W2096045296 @default.
- W2967284043 cites W2098920479 @default.
- W2967284043 cites W2100666674 @default.
- W2967284043 cites W2101192596 @default.
- W2967284043 cites W2104556654 @default.
- W2967284043 cites W2105431972 @default.
- W2967284043 cites W2109063989 @default.
- W2967284043 cites W2110420249 @default.
- W2967284043 cites W2112555704 @default.
- W2967284043 cites W2116816874 @default.
- W2967284043 cites W2121064165 @default.
- W2967284043 cites W2121448090 @default.
- W2967284043 cites W2122415095 @default.
- W2967284043 cites W2123039957 @default.
- W2967284043 cites W2125096244 @default.
- W2967284043 cites W2125258157 @default.
- W2967284043 cites W2125281349 @default.
- W2967284043 cites W2127345419 @default.
- W2967284043 cites W2127755290 @default.
- W2967284043 cites W2129491200 @default.
- W2967284043 cites W2132212568 @default.
- W2967284043 cites W2132813534 @default.
- W2967284043 cites W2133440505 @default.
- W2967284043 cites W2133530652 @default.
- W2967284043 cites W2133979383 @default.
- W2967284043 cites W2135191756 @default.
- W2967284043 cites W2136000921 @default.
- W2967284043 cites W2149362635 @default.
- W2967284043 cites W2149483505 @default.
- W2967284043 cites W2150965448 @default.
- W2967284043 cites W2152442798 @default.
- W2967284043 cites W2152771638 @default.
- W2967284043 cites W2155982642 @default.
- W2967284043 cites W2156888060 @default.
- W2967284043 cites W2157537183 @default.
- W2967284043 cites W2157703514 @default.
- W2967284043 cites W2158852772 @default.
- W2967284043 cites W2162000793 @default.
- W2967284043 cites W2162949579 @default.
- W2967284043 cites W2163164035 @default.
- W2967284043 cites W2164970926 @default.
- W2967284043 cites W2165558345 @default.
- W2967284043 cites W2169332402 @default.
- W2967284043 cites W2170504031 @default.
- W2967284043 cites W2195971973 @default.
- W2967284043 cites W2218610481 @default.